Dr. Ahluwalia on Using Precision Medicine to Treat Brain Metastases

Video

Manmeet Ahluwalia, MD, FACP, Miller Family Endowed Chair in Neuro-Oncology and Head of Operations, Burkhardt Brain Tumor NeuroOncology Center, discuses a new classification system for brain metastases.

Manmeet Ahluwalia, MD, FACP, Miller Family Endowed Chair in Neuro-Oncology and Head of Operations, Burkhardt Brain Tumor NeuroOncology Center, discuses a new classification system for brain metastases.

Tumors are now classified based on molecular profiling, rather than the grade of the tumor. This allows oncologists to take a precision medicine approach to treatment, and use targeted therapies to go after actionable mutations, says Ahluwalia.

The goal is to minimize the toxicities of treatment while maximizing the benefit, he adds.

Patients with brain metastases are unique, says Ahluwalia, as patients have many different primary tumors. Lung cancer is the most common cause of brain metastases.

Every patient should be treated differently, and their extracranial disease as well as the disease of the brains should be considered.

The patient should also be treated with a multidisciplinary approach.

<<<

View more from the 2016 SNO Annual Meeting

Related Videos
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center